Cell News and Research

RSS

Mutated Nesprin4 protein prevents hearing

Because half of all instances of hearing loss are linked to genetic mutations, advanced gene research is an invaluable tool for uncovering causes of deafness - and one of the biggest hopes for the development of new therapies. Now Prof. Karen Avraham of the Sackler Faculty of Medicine at Tel Aviv University has discovered a significant mutation in a LINC family protein - part of the cells of the inner ear - that could lead to new treatments for hearing disorders.

29 Jan 2013

Bone Medical announces initial findings from BN006 proof of concept RA study

Bone Medical Ltd, a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology.

29 Jan 2013

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

29 Jan 2013

Minimally invasive islet transplantation reverses progression of atherosclerosis in type 1 diabetics

Minimally invasive islet transplantation for patients with type 1 diabetes achieves insulin independence and reverses the progression of atherosclerosis in the first few years after transplant, according to a University of Illinois at Chicago study.

29 Jan 2013

Stem cells from bone marrow or fat improve recovery after stroke in rats

Stem cells from bone marrow or fat improve recovery after stroke in rats, finds a study published in BioMed Central's open access journal Stem Cell Research & Therapy. Treatment with stem cells improved the amount of brain and nerve repair and the ability of the animals to complete behavioural tasks.

29 Jan 2013

Researchers unveil first maturation-based ‘disease in a dish’ model for ARVD/C

Most patients with an inherited heart condition known as arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) don't know they have a problem until they're in their early 20s. The lack of symptoms at younger ages makes it very difficult for researchers to study how ARVD/C evolves or to develop treatments. A new stem cell-based technology created by 2012 Nobel Prize winner Shinya Yamanaka, M.D., Ph.D., helps solve this problem.

29 Jan 2013

Emotional stress can reduce prostate cancer drugs’ effectiveness

Not surprisingly, a cancer diagnosis creates stress. And patients with prostate cancer show higher levels of anxiety compared to other cancer patients. A new study by researchers at Wake Forest Baptist Medical Center indicates that stress is not just an emotional side effect of the diagnosis; it also can reduce the effectiveness of prostate cancer drugs and accelerate the development of prostate cancer.

29 Jan 2013

Five genes hold key to meningioma make up

Research published in Science shows that mutations in five genes characterize most meningiomas.

28 Jan 2013

Skin cells transformed into heart cells for research into cardiomyopathy

...

28 Jan 2013

Researchers investigate acidity in solid tumors to determine if pH levels play a role in cell invasion

Researchers at Moffitt Cancer Center and colleagues at Wayne State University School of Medicine investigated the acidity in solid tumors to determine if pH levels play a role in cancer cell invasion in surrounding tissues.

28 Jan 2013

Temple scientists to solve long-standing mystery in sepsis

Scientists at the Center for Translational Medicine at the Temple University School of Medicine are inching closer to solving a long-standing mystery in sepsis, a complex and often life-threatening condition that affects more than 400,000 people in the U.S. every year.

28 Jan 2013

Paper says hospitals that do treat patients with anemia have better outcomes

Up to one-third of patients undergoing surgery in Ontario have a treatable form of anemia but are not optimally treated for it.

28 Jan 2013

The LINC complex essential for hearing

In this issue of the Journal of Clinical Investigation, Karen Avraham and colleagues at Tel Aviv University identified a genetic mutation in two families with hereditary high frequency hearing loss. The mutated gene, which has not previously been linked to hearing loss, encodes NESP4, a protein that is expressed in the outer nuclear membrane (ONM) of the hair cells of the ear.

28 Jan 2013

Evidence links HPV16 to focal cortical dysplasia type IIB

Researchers at Shriner's Hospital Pediatric Research Center at the Temple University School of Medicine, and the University of Pennsylvania have evidence linking the human papillomavirus 16 (HPV16) - the most common cause of cervical cancer - to a common form of childhood epilepsy.

28 Jan 2013

Study sheds new light on learning and memory-making

In experiments on rats outfitted with tiny goggles, scientists say they have learned that the brain's initial vision processing center not only relays visual stimuli, but also can "learn" time intervals and create specifically timed expectations of future rewards.

28 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Sanofi Canada announces new option for emergency treatment of anaphylaxis

Sanofi Canada announces a new option for the emergency treatment of anaphylaxis. Allerject is the first and only 'talking' epinephrine auto-injector in Canada.

28 Jan 2013

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

The U. S. Patent and Trademark Office recently issued a patent to the U. S. Department of Health and Human Services involving resiniferatoxin, or RTX, an experimental compound that represents a potential new class of drugs to alleviate the intractable pain that can occur in people with advanced cancer, severe arthritis, and other extremely chronic conditions.

28 Jan 2013

Parental behavior, quality preschool and diet can effectively raise children's IQ

Supplementing children's diets with fish oil, enrolling them in quality preschool, and engaging them in interactive reading all turn out to be effective ways to raise a young child's intelligence, according to a new report published in Perspectives on Psychological Science, a journal of the Association for Psychological Science.

28 Jan 2013

FDA accepts Genzyme’s LEMTRADA sBLA for review

Genzyme, a Sanofi Company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental Biologics License Application (sBLA) file seeking approval of LEMTRADA (alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS).

28 Jan 2013